Here are six observations:
1. In 2016, the market was valued at $5.68 billion.
2. Primary cemented hip replacement devices dominate the market.
3. A growing number of patients as well as an increasing number of osteoarthritis and rheumatoid arthritis cases will spur market growth through 2022.
4. The costliness of hip reconstruction procedures and devices will hinder market growth.
5. North America leads the market, driven by the demand for minimally invasive procedures and existence of strong hip reconstruction device vendors.
6. United Orthopedic, Exactech, Corin, Braun Melsungen, DePuy Synthes and Stryker represent key market players.
More articles on devices:
Under the microscope: How nano-level surface technology helps improve early patient outcomes and surgeon income in the new incentivized pay-for-performance era
How self-funded health plans boost patient satisfaction with medical innovation
Amedica adjourns stockholder special meeting — 5 takeaways
